Abstract
The capacity of ultrasensitive quantification is highly desirable in many clinical and pharmaceutical applications, such as the PK study of low-dose administration and quantification of low-abundance markers in circulating systems. Nonetheless, this task is highly challenging even for a LC-MS/MS approach, due to the extremely low levels of analytes and the highly complex matrices. Here we describe a robust method for the ultrasensitive quantification of therapeutic agents or clinical markers in highly complex biological systems. This is achieved by the combination of a selective solid-phase extraction (SPE) with a highly sensitive capillary LC (μLC)-MS/MS analysis. Comparing to a conventional LC-MS/MS, a μLC-MS/MS provides much higher sensitivity due to the lower peak dilution. SPE washing and elution conditions were optimized so that target drugs are selectively extracted from the biological matrix. By eliminating most undesirable matrix components, this selective SPE procedure enabled a high sample loading volume on the μLC column without compromising chromatographic performance and operational robustness, and helped to achieve ultralow detection limits. Sufficient μLC separation was employed in order to further improve analytical sensitivity and to decrease matrix effects. To show the application of this strategy, three paradigms, respectively, the quantifications of (1) corticosteroids after an intravitreous injection, (2) an anticancer agent after a low-dose treatment, and (3) several vitamin D (VitD) metabolites in plasma, are introduced in this chapter. Typically, low pg/mL LOQ were achieved, and the linearity, accuracy, and precision of these developed methods were excellent.
Collectively, this strategy enables the ultrasensitive, accurate, and robust LC-MS-based quantification of extremely low levels of drug/markers in biological samples, which were previously approachable only by ELISA or RIA methods.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Vissers JPC, Claessens HA, Cramers CA (1997) J Chromatogr A 779:1–28
Wilm M, Shevchenko A, Houthaeve T, Breit S, Schweigerer L, Fotsis T, Mann M (1996) Nature 379:466–469
Emmett MR, Caprioli RM (1994) J Am Soc Mass Spectrom 5:605–613
Qu J, Qu Y, Straubinger RM (2007) Anal Chem 79:3786–3793
Yu HY, Straubinger RM, Cao J, Wang H, Qu J (2008) J Chromatogr A 1210:160–167
Duan XT, Weinstock-Guttman B, Wang H, Bang EJ, Li J, Ramanathan M, Qu J (2010) Anal Chem 82:2488–2497
Qu J, Wang YM, Luo GA (2001) J Chromatogr A 919:437–441
Olsen TW, Feng X, Warner K, Conston SR, Sierra DH, Folden DV, Smith ME, Cameron JD (2006) Am J Ophthalmol 142:777–787
Beer PM, Bakri SJ, Singh RJ, Liu WG, Peters GB, Miller M (2003) Ophthalmology 110:681–686
Alexander MS, Kiser MM, Culley T, Kern JR, Dolan JW, McChesney JD, Zygmunt J, Bannister SJ (2003) J Chromatogr B 785:253–261
Kumar GN, Walle UK, Bhalla KN, Walle T (1993) Res Commun Chem Pathol 80:337–344
Kuh HJ, Jang SH, Wientjes MG, Au JLS (2000) J Pharmacol Exp Ther 293:761–770
Gaspar JR, Qu J, Straubinger NL, Straubinger RM (2008) Analyst 133:1742–1748
Saito Y, Jinno K, Greibrokk T (2004) J Sep Sci 27:1379–1390
Stokvis E, Ouwehand M, Nan LGAH, Kemper EM, van Tellingen O, Rosing H, Beijnen JH (2004) J Mass Spectrom 39:1506–1512
Parise RA, Ramanathan RK, Zamboni WC, Egorin MJ (2003) J Chromatogr B 783:231–236
Hou WY, Watters JW, McLeod HL (2004) J Chromatogr B 804:263–267
Grozav AG, Hutson TE, Zhou X, Bukowski RM, Ganapathi R, Xu Y (2004) J Pharm Biomed 36:125–131
Guo W, Johnson JL, Khan S, Ahmad A, Ahmad I (2005) Anal Biochem 336:213–220
Wang LZ, Goh BC, Grigg ME, Lee SC, Khoo YM, Lee HS (2003) Rapid Commun Mass Spectrom 17:1548–1552
Gustafson DL, Long ME, Zirrolli JA, Duncan MW, Holden SN, Pierson AS, Eckhardt SG (2003) Cancer Chemother Pharm 52:159–166
Smolders J, Damoiseaux J, Menheere P, Hupperts R (2008) J Neuroimmunol 194:7–17
Houghton LA, Vieth R (2006) Am J Clin Nutr 84:694–697
Zerwekh JE (2008) Am J Clin Nutr 87:1087s–1091s
Norman AW, Okamura WH, Farachcarson MC, Allewaert K, Branisteanu D, Nemere I, Muralidharan KR, Bouillon R (1993) J Biol Chem 268:13811–13819
Seo EG, Norman AW (1997) J Bone Miner Res 12:598–606
Carter GD (2009) Clin Chem 55:1300–1302
Roth HJ, Schmidt-Gayk H, Weber H, Niederau C (2008) Ann Clin Biochem 45:153–159
Haddad JG (1971) J Clin Endocr Metab 33:992–995
Jones G (1978) Clin Chem 24:287–298
Khatri BO (2000) Ther Apher Off J Int Soc Apher Jpn Soc Apher 4:263–270
Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A (2006) JAMA 296:2832–2838
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Yu, H., Duan, X., Qu, J. (2012). Highly Sensitive Pharmaceutical and Clinical Analysis Using Selective Solid-Phase Extraction Coupled to Microflow Liquid Chromatography and Isotope-Dilution Mass Spectrometry. In: Xu, Q., Madden, T. (eds) LC-MS in Drug Bioanalysis. Springer, Boston, MA. https://doi.org/10.1007/978-1-4614-3828-1_4
Download citation
DOI: https://doi.org/10.1007/978-1-4614-3828-1_4
Published:
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4614-3827-4
Online ISBN: 978-1-4614-3828-1
eBook Packages: Chemistry and Materials ScienceChemistry and Material Science (R0)